Robert Daber

Dr. Daber is Vice President of Science and Technology Development and leads the Sample to Answer Center of Excellence at Labcorp, where he oversees scientific, technological, and translational strategy across advanced genomic diagnostics. He is a diplomate of the American Board of Medical Genetics and Genomics (Clinical Cytogenetics) and a fellow of the American College of Medical Genetics. He is certified by the New York State Department of Health as a director of genetic testing (molecular) and molecular and cellular tumor markers.

Dr. Daber earned his B.S. in Biochemistry and Applied Molecular Biology from the University of Maryland Baltimore County and his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania School of Medicine. He completed postdoctoral fellowship training at the Children’s Hospital of Philadelphia.

Prior to joining Labcorp, Dr. Daber served in senior scientific and executive leadership roles across multiple genomic diagnostics organizations, including Chief Scientific Officer at Invitae and Chief Technology Officer and President at Genosity. His work has focused on advancing clinical genomics, oncology diagnostics, informatics, and the scale up of high complexity laboratory operations.

Dr. Daber has authored numerous peer reviewed publications and abstracts in leading scientific journals, including Nature, Nature Communications, The American Journal of Human Genetics, Genetics in Medicine, Journal of Molecular Diagnostics, and Clinical Cancer Research.

Areas of Support: Molecular Genetics and Genomics, Molecular Oncology

Memberships: FACMG

Board Certifications: ABMGG

Publications

1. Ting YL, Williams TJ, Metz H, Li M, Stetler M, Knight Johnson AE, Bunker BD, Pineda-Alvarez DE, Daber RD., Diagnostic yield of exome reanalysis over time: Contribution of reevaluation type, timing, and patient phenotype. Genet Med. 2026 Mar 4;28(5):102549. doi: 10.1016/j.gim.2026.102549. PMID: 41795598

2. Garcia-Murillas I, Cutts RJ, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, Sidhu K, Daber R, Hubert B, Graybill C, DeFord PM, Wooten DJ, Zhao J, Ellsworth RE, Johnston SRD, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith IE, Korn WM, Turner NC. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Res Treat. 2025 Feb;209(3):493-502. doi: 10.1007/s10549-024-07508-2. Epub 2024 Oct 18. PMID: 39424680; PMCID: PMC11785695.

3. Chong JX, Berger SI, Baxter S, Smith E, Xiao C, Calame DG, Hawley MH, Rivera-Munoz EA, DiTroia S; Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium; Bamshad MJ, Rehm HL. Considerations for reporting variants in novel candidate genes identified during clinical genomic testing. Genet Med. 2024 Oct;26(10):101199. doi: 10.1016/j.gim.2024.101199. Epub 2024 Jun 26. PMID: 38944749; PMCID: PMC11456385.

4. Zhao J, Reuther J, Scozzaro K, Hawley M, Metzger E, Emery M, Chen I, Barbosa M, Johnson L, O'Connor A, Washburn M, Hartje L, Reckase E, Johnson V, Zhang Y, Westheimer E, O'Callaghan W, Malani N, Chesh A, Moreau M, Daber R. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Mol Diagn Ther. 2023 Nov;27(6):753-768. doi: 10.1007/s40291-023-00670-1. Epub 2023 Aug 26. PMID: 37632661; PMCID: PMC10590345.

5. Wojcik MH, Reuter CM, Marwaha S, Mahmoud M, Duyzend MH, Barseghyan H, Yuan B, Boone PM, Groopman EE, Délot EC, Jain D, Sanchis-Juan A; Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium; Starita LM, Talkowski M, Montgomery SB, Bamshad MJ, Chong JX, Wheeler MT, Berger SI, O'Donnell-Luria A, Sedlazeck FJ, Miller DE. Beyond the exome: What's next in diagnostic testing for Mendelian conditions. Am J Hum Genet. 2023 Aug 3;110(8):1229-1248. doi: 10.1016/j.ajhg.2023.06.009. PMID: 37541186; PMCID: PMC10432150.

6. Glodzik D, Selenica P, Rogge RA, Silverman IM, Mandelker D, Harris S, Zhao J, Zinda M, Veloso A, Malani N, Riaz N, Koehler M, Daber RD, Johnson V, Rimkunas V, Reis-Filho JS. Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. J Mol Diagn. 2023 May;25(5):295-310. doi: 10.1016/j.jmoldx.2023.02.004. Epub 2023 Mar 20. PMID: 36944408; PMCID: PMC10340082.

7. Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023 Apr;616(7957):553-562. doi: 10.1038/s41586-023-05776-4. Epub 2023 Apr 13. PMID: 37055640; PMCID: PMC7614605.

8. Glodzik D, Selenica P, Rogge RA, Silverman IM, Mandelker D, Harris S, Zhao J, Zinda M, Veloso A, Malani N, Riaz N, Koehler M, Daber RD, Johnson V, Rimkunas V, Reis-Filho JS. Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. J Mol Diagn. 2023 May;25(5):295-310. doi: 10.1016/j.jmoldx.2023.02.004. Epub 2023 Mar 20. PMID: 36944408.